Publication | Closed Access

A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non‐small cell lung cancer

MedicinePharmacologyPathologyChk1 InhibitorBronchial NeoplasmCancer TreatmentOncologyRadiation OncologyLung CancerMolecular Oncology